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1. Introduction 
Meconium stained amniotic fluid (MSAF), which occurs in about 10-15% of all pregnancies 
[Wiswell TE. et al., 1990], is common in term births and especially in post-date deliveries. 
Τhe etiology and pathophysiology of MSAF is poorly understood. While the more advanced 
maturation process of the gastrointestinal tract may account for the higher rates of MSAF in 
post-date deliveries, it is generally believed that the presence of MSAF in other 
circumstances is a marker of fetal distress and may be associated with adverse fetal and 
neonatal outcome [Woods JR. et al., 1994; Krebs HB. et al., 1980; Mazor M. et al., 1998].  
A relationship of MSAF with stillborn infants, abnormal fetal heart-rate (FHR) tracings, 
neonatal encephalopathy, respiratory distress (meconium aspiration syndrome, MAS) and 
abnormal neurologic outcome is reported in the literature. The finding of MSAF is 
associated with multiple markers of fetal distress, as meconium-stained infants have in 
general lower scalp pHs and lower umbilical cord artery pHs in comparison with infants 
born through clear amniotic fluid [Nathan L. et al., 1994; Ramin K. et al., 1994; Starks GD., 
1980]. Additionally, infants born through MSAF have lower Apgar scores in the first and 
fifth minute after delivery [Wiswell TE. et al., 1990; Clifford SH., 1945]. However, in the vast 
majority of cases, no major problems occur in infants born through MSAF. 
The term “meconium aspiration syndrome (MAS)” describes neonates born through MSAF, 
who present respiratory distress which cannot be otherwise explained. MAS is the most 
frequent complication diagnosed among infants born through MSAF, with an incidence of 
about 5% in these cases [Wiswell TE. et al., 1993; Cleary GM. et al., 1998]. Meconium stained 
infants are considered 100 times more likely to develop MAS, compared with infants born 
through clear amniotic fluid [Fleischer A., et al., 1992]. The severity of this syndrome is 
demonstrated by the fact that published data report that about one-third to one-half of 
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neonates with MAS will require mechanical ventilation, one-quarter will develop 
pneumothoraxes and one in twenty will die, although the death rate has declined 
appreciably since the 1990s as a result of successful airway management in the delivery 
room, better ventilatory techniques and improvement in supportive neonatal care 
(thermoregulation, parenteral nutrition) [Wiswell TE. et al., 1993; Cleary GM. et al., 1998].  
It is noteworthy that the significantly higher rates of admission to newborn intensive care 
units for neonates born through MSAF in comparison with those born through clear 
amniotic fluid underlines the strong association between MSAF and fetal distress; the 
greater experience, moreover, gained in this area has also yielded useful data about the cost-
effective management of such cases. It was estimated that approximately 24% of meconium 
stained neonates were admitted to newborn intensive care units, compared to 7% of those 
born through clear amniotic fluid [Nathan L. et al., 1994].  
Although the incidence of MSAF and MAS is high, there remains a distinct paucity of 
literature describing the neurological development of either children born through MSAF or 
those with MAS. The aim of this Chapter is to review studies which examine the potential 
association of MSAF and MAS with fetal and neonatal brain injury in order to investigate 
the incidence of this condition, the possible pathogenetic pathways of fetal brain injury in 
MSAF and the optimal means of recognizing and preventing these complications.   
1.1 Historical aspects 
It was the famous ancient Greek philosopher Aristotle who, first describing meconium 
stained amniotic fluid, conferred on this condition the name “meconium-arion”, literally 
meaning “opium-like”. His use of this term may have been due to his belief that MSAF 
induced fetal sleep and his knowledge that it was also associated with fetal deaths and 
neonatal depression, or else it may have arisen because meconium resembles the black, tarry 
consistency of processed opium.  Several publications from the 1600s reported MSAF as a 
sign of death or impending death of the fetus. The first description of in utero aspiration of 
meconium and MAS was published in 1918 [Reed CB., 1918]. An explanation for the 
pathogenetic mechanism was based on the hypothesis that in utero anoxia could relax the 
anal sphincter and result in meconium passage. Other investigators maintained that 
asphyxia leads to meconium passage because of increased intestinal peristalsis [Brews A., 
1948]. The critical point of hypoxia that is needed for meconium passage was first described 
in a study which found that umbilical venous oxygen saturation levels below 30% were 
associated with meconium passage [Walker J., 1954]. In 1945, Clifford, in a research study 
supporting the need for resuscitation in such cases and basing his views on the 
complications observed in neonates, reported a mortality rate of approximately 6% and a 
morbidity rate of about 60% among infants born through MSAF [Steer PJ. et al., 1989].  
Useful conclusions with regard to MSAF and MAS were disclosed in the National Institute 
of Neurological and Communicative Disorders and Stroke Collaborative Perinatal Project 
(CPP) of the late 1950s and 1960s. In this project, more than 42,000 children were followed as 
from delivery for possible future identification of cerebral palsy (CP), mental retardation 
(MR) and other abnormal neurologic findings. It was found that 10.3% of all live-born 
infants in the CPP had had meconium staining. Neonatal mortality rate for the stained 
group was about 3.3%, compared to 1.7% among infants born through clear amniotic fluid 
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[Fujikura T., et al., 1975]. The incidence of MAS among infants born through MSAF in the 
CPP was about 8.7% [Naeye RL., 1992]. In contrast with the extremely decreased mortality 
rates of this complication in the present day, it was noted that ultimately 63% of neonates 
who developed MAS in the CPP died. It is notable that from 1957, the hypothesis that 
meconium stained neonates had a significantly higher risk of developing neurologic 
disorders in the future was supported in the literature [Brown CA. et al., 1957].  
The greatly improved results in mortality and morbidity rates today in cases of infants 
diagnosed with MAS are attributable to the highly successfully applied aggressive airway 
management that has been followed by pediatricians in meconium stained neonates since 
the 1970s [Wiswell TE., et al., 2000]. Although large randomized controlled clinical trials do 
not support the need for intratracheal intubation and suctioning, the generally followed 
practice of obstetrical oro- and nasopharyngeal suctioning and postpartum intratracheal 
suctioning of meconium stained infants in the delivery room plays an important role in 
prevention of severe complications arising from the meconium aspiration syndrome 
[Wiswell TE., et al., 2000]. On the other hand, maneuvers like intrapartum oro- and 
nasopharyngeal suctioning prior to delivery of the baby’s shoulders or amnioinfusion of 
normal saline or lactated Ringer’s infusion into the uteri of women with MSAF do not avert 
the development of MAS [Vain NE. et al., 2004; Fraser WD. et al., 2004].    
2. Mechanisms of meconium passage 
Meconium is a viscous green liquid consisting of gastrointestinal secretions, bile, bile acids, 
mucus, pancreatic juice, cellular debris, amniotic fluid and swallowed vernix caseosa, 
lanugo and blood [Wiswell TE. et al., 1993]. Approximately 60-200 gr. of meconium are 
found in a term infant’s intestine. The many possible pathophysiological pathways of 
intraamniotic meconium passage all have the same origin, which is ante- or intrapartum 
asphyxia. Several investigators have argued that in utero anoxia could relax the anal 
sphincter tone of the embryo [Reed CB., 1918], while others have expressed the hypothesis 
that anoxia could increase intestinal peristalsis [Brews A., 1948]. In any case, both these 
pathways originate from asphyxia and lead to intraamniotic meconium passage. 
Additionally, the theory of compression of the fetal head or umbilical cord which produces 
a vagal response and finally leads to meconium passage is supported in the published 
literature [Miller FC. et al., 1981]. The important role of hypoxia was well documented after 
clinical observations that umbilical venous oxygen saturation levels below 30% were 
associated with meconium passage [Walker J. et al., 1954]. There are also theories which 
propose a potential pathogenetic role of intrauterine infection leading to meconium passage, 
as the rate of intraamniotic infection is shown to be significantly higher in women with 
MSAF [Wen TW. et al., 1993; Vrachnis N. et al., 2010]. 
On the other hand, in the majority of cases, the presence of meconium is probably a 
physiologic maturational event. Meconium passage is rare before the 37th week of gestation, 
but may occur in more than 35% of pregnancies after the 42nd week of gestation [Nathan L. 
et al., 1994]. 
However, how can one make estimates of the amount of time that has passed between fetal 
defecation and birth?  There are clear-cut indications.  Freshly passed meconium is a thick, 
viscous shimmering black-green colored substance. With the progress of time, the color of 
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MSAF will change to brown and finally to tan or yellow. That is why the yellow-colored 
appearance of MSAF is synonymous with the term “old” meconium.  
Additionally, it is generally believed that the duration between defecation and delivery can 
be estimated by the color of placental staining. Acute staining is slimy with a dark-green 
color, chronic staining has a characteristic muddy-brown appearance (over six hours of 
exposure), while very remotely passed meconium is light tan.   
3. MSAF and brain injury   
3.1 MSAF and adverse neurodevelopmental outcomes 
Although large prospective epidemiologic studies specifically following a group of neonates 
born through MSAF for future development of neurologic handicaps are absent from the 
published literature, there are several reports which link the pathogenetic role of meconium 
passage with a variety of neurolodevelopmental disorders. 
A strong relationship between MSAF and symptoms like hypotonia, lethargy and seizures 
in infants born through MSAF is documented in the literature [Brown CA. et al., 1957]. 
Additionally, Grafe studied cases of brain injury in 83 stillborns and 13 infants that occurred 
within one hour from delivery [Grafe MR., 1994]. A higher rate of neurological 
complications was noted among infants born through MSAF if meconium staining of the 
placenta was present, while the major neurologic pathological finding was white-manner 
gliosis or necrosis. The key role of placental meconium staining was also observed in a 
recent study published in 2005 which stated that meconium-associated vascular necrosis of 
the placenta is the main etiological factor associated with neurologic impairment in infants 
[Redline RW., 2005] (Figure 1). 
Research studies have also recognized a strong relationship of meconium passage with 
adverse neurologic outcome, especially in premature labor. Meconium in premature labor is 
considered to be a higher risk factor for future neurologic disorders compared to term 
delivery. In a study of Kalis et al., 41% of premature infants born through MSAF were 
diagnosed as having cerebral palsy (CP), compared to 10% in the same group with clear 
amniotic fluid. The incidence of CP in term pregnancy when meconium was present was 
reported as 0.4%, compared to 0.3% in a population without any obstretical risk [Kalis V. et 
al., 2001].    
Information and data from the CPP were examined by several investigators in order to 
exclude safe conclusions. A group of 50 children from the CPP diagnosed with neurological 
disorders, like moderate or severe motor disability and severe MR, was studied and 
compared to a large control population. Those with severe disorders were more than twice 
as likely to have been born through MSAF (40.8% vs 19.1%) [Nelson KB. et al., 1977]. The 
same investigator found that the rate of CP among children with a birthweight over 2500 gr. 
was about 3/1000 if there was no history of obstetrical problems, while it was 4/1000 when 
neonates were born through MSAF in the absence of further obstetrical complications 
[Nelson KB., 1989]. Of particular interest was the increased CP rate (94/1000) when there 
was a history of MSAF and a 5-minute Apgar score below 3 [Nelson KB., 1989]. In cases of 
neonates with a birthweight below 2500 gr. born through MSAF, the estimated rate of CP 
was approximately 15/1000. Additionally, 12/1000 of these low-birthweight meconium 
stained infants developed seizures in the absence of CP [Nelson KB. et al., 1984]. 
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Fig. 1.  Pathogenetic pathway of direct in vivo vasoconstriction on umbilical cord and 
placental vessels from meconium (meconium stained placenta), that leads to cerebral 
cortical and subcortical brain damage, in comparison with normal neural development in an 
infant born through clear amniotic fluid without placenta lesions (infracts or 
vasoconstriction). 
In another study, a group of 75 babies diagnosed with CP was analyzed [Shields JR. et al., 
1988]. The aim of this research was to investigate the potential correlation between 
MSAF/MAS and future development of CP. The results supported this hypothesis, as 41% 
of babies with CP had been born through MSAF, while 21% had been affected by MAS. 
Similar results were reported in several other studies that found an increased rate of CP and 
periventricular leukomalacia (PVL) among meconium stained premature infants [Gaffney 
G. et al., 1994; Spinillo A. et al., 1997; Spinillo A. et al., 1998]. 
An interesting research studied the incidence of autistic disorder in neonatal intensive care 
unit survivors. Five thousand two hundred seventy-one (5271) children were followed for 
neurodevelopmental disorders for a five-year period after discharge. Autistic disorder was 
diagnosed in 18 cases, while 57 developed CP. Obstetrical history of MAS was found 
significantly higher in the group with autistic disorder (22%) or CP (8.8%), compared with 
the control population of neonatal care units survivors without MAS [Matsuishi T. et al., 
1999]. 
Several studies have also found an increased rate (up to sevenfold) of seizures during the 
neonatal period among infants born through MSAF in comparison with cases in which 
amniotic fluid was clear [Nathan L. et al., 1994; Berkus MD. et al., 1994; Sato S. et al., 2003]. 
This observation is important as seizures constitute a predictive factor of subsequent 
neurological adverse outcome. In some of these cases of seizures during the neonatal period, 
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even in the absence of signs of hypoxic-ischemic encephalopathy, perisagittal cerebral 
infracts were present [Sato S. et al., 2003]. A hypothesis that pre-existing neurological injury 
prior to delivery takes place in the majority of meconium stained infants, rather than 
intrapartum injury, was supported by a recent research [Blackwell SC. et al., 2001]. In this 
study, the risk for developing seizures among neonates with severe MAS was found to be 
independent from pH levels of the umbilical cord artery, which are associated with 
intrapartum fetal distress. According to these findings, the conclusion that non-hypoxic-
ischemic mechanisms may also cause fetal and neonatal brain injury seems correct.  
3.2 MSAF and pathogenesis of brain injury 
Thus, which is the pathogenetic mechanism that leads to brain injury in cases of infants born 
through MSAF? The pathophysiologic mechanisms that cause CP remain controversial and 
cannot be associated with birth injury or intrapartum hypoxic-ischemic insults alone [Kuban 
KCK et al., 1994]. At the present time, several markers are used for prognostic purposes, 
with fetal heart rate tracing, the Apgar score in the first and fifth minute after delivery or the 
presence of recurrent neonatal seizures providing means to indicate the potential for CP in 
the future. In particular, the latter prognostic factor seems to have greater validity than other 
perinatal characteristics [Nelson KB. et al., 1977; Kuban KCK et al., 1994]. Of course, 
ultrasonographic appearance of periventricular leukomalacia is the most reliable sign of 
future CP development [Kalis V. et al., 2001]. Nevertheless, none of these markers explains 
the pathogenesis of brain injury after meconium passage, since they are considered to be the 
consequence rather than the cause of the processes leading to CP. 
In order to investigate the potential pathogenetic mechanism of fetal and neonatal brain 
injury due to MSAF it is necessary to emphasize the possible conditions that lead to 
meconium passage in utero, these conditions being: hypoxia-anoxia status, intrauterine 
infection or maturation progress. Consequently, meconium staining is strongly correlated 
with disorders that could affect the fetus: chorioamnionitis, premature rupture of 
membranes, abruption placentae and large placental infarcts [Naeye RL., 1992]. Some 
fetuses suffer acute or chronic episodes, severe enough to cause brain injury, but not 
intrauterine death. If the stress disappears, the fetus can resume its normal status and not 
present postpartum depression with low Apgar scores or low umbilical cord artery pH. The 
neonate may seem neurologically healthy for months after delivery; however, severe 
neurodevelopmental disorders could be diagnosed years after birth. Similarly, the presence 
of negative prognostic factors, such as abnormal fetal heart rate tracing or low Apgar scores, 
may reflect an insult that took place long before delivery (hours to days to even weeks or 
months) rather than of more immediate intrapartum difficulties.  
These observations lead to the conclusion that the intrauterine environment and the causes 
giving rise to intraamniotic meconium passage are also involved in the pathophysiology of 
fetal brain injury due to MSAF. It is clear that meconium passage could be a major factor in 
the pathogenesis of neurological disorders.  
The main pathogenetic pathways are two:  
i. Meconium and its components (bile acids) may have a direct vasoconstrictive effect on 
umbilical and placental vessels [Kalis V. et al., 2001] (Figure 1). This hypothesis was 
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studied in a research seeking to investigate a potential mechanism of fetal ischemia 
caused by vasoconstriction of placental or umbilical vessels [Altshuler G. et al., 1989; 
Altshuler G., 1995]. Vasoactive substances of meconium could cross into the fetal 
circulation and cause ischemia of cerebral vessels or render pulmonary vessels more 
reactive, resulting in persistent pulmonary hypertension of the newborn. Additionally, 
an in vitro experiment that was performed exposing excised umbilical venous tissue to 
meconium showed substantial vasoconstriction. Although the specific constituent was 
not identified, the hypothesis that MSAF could cause in vivo placental and umbilical 
cord vasoconstriction was correct, as the agent was found to be heat-labile.  
This pathogenetic pathway underlines the major role of meconium-induced placental 
necrosis, due to vasoconstrictive effects on umbilical and placental vessels, in fetal brain 
injury. Meconium in the amniotic fluid may sometimes initiate vasoconstriction on 
umbilical and placental vessels, which leads to cerebral cortical and subcortical brain 
damage and finally ischemic-hypoxemic CP, as it may reduce the venous return of 
oxygenated blood from the placenta to the fetus [Naeye RL., 1995]. This theory is in 
agreement with previously mentioned studies which report that a higher rate of 
neurological complications is noted among infants born through MSAF if meconium 
staining of the placenta was present, as meconium-associated vascular necrosis of the 
placenta is thought to be the main etiological factor associated with neurologic 
impairment in infants [Redline RW., 2005]. As established by Altshuler, with the 
passage of meconium into the fetal sac, it takes a minimum of four to twelve hours for 
the meconium to diffuse to and into the lumens of placental and umbilical cord vessels 
and become pathogenetic, inducing vasoconstriction [Altshuler G., 1995]. 
ii. Meconium causes intraamniotic infection and results in a release of fetal cytokines and 
eicosanoids (tumor necrosis factor alpha-TNF-a-, interleukin 1 beta-IL-1β-, interleukin 6 
-IL-6-, interleukin 8-IL-8-, leukotriene B4, thromboxane B2) which can damage 
myelinogenesis in periventricular white matter and lead to periventricular 
leukomalacia as shown in Figure 2 [Kalis V. et al., 2001; Le Bouar G. et al., 2002; 
Malamitsi-Puchner A. et al., 2006]. The increased incidence of intrauterine infections in 
the presence of MSAF, as well as the frequent findings of inflammatory lesions in the 
placenta, umbilical cord, fetal membranes and lungs, underscores the major role of 
inflammation in the pathogenesis of fetal brain injury. It is well known that 
proinflammatory fetal cytokines, oxidants and eicosanoids produce an oxidant 
environment with deleterious and ischemic effects on fetal neural tissue [Naeye RL., 
1995; Wu JM. et al., 1995]. 
It is however more likely that the etiology of fetal brain injury in cases of in utero meconium 
passage is synergic. This means that both above mentioned pathogenetic pathways could 
play an important role in the development of brain damage, but when there is a 
combination of the two main factors (both direct vasoconstriction on placental vessels and 
intrauterine infection), then the result becomes more severe. Highly interesting studies are 
accordingly being carried out based on both the toxic vasoconstrictive role of meconium and 
the deleterious effects of fetal cytokines and other infection-related factors in the presence of 
MSAF in order to elucidate the pathogenetic mechanism of fetal brain injury [Benirschke K., 
2001]. 
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Fig. 2. Pathogenetic pathway of intraamniotic infection due to meconium passage that 
results in a release of cytokines and eicosanoids from fetal lungs which can damage 
myelinogenesis and lead to periventricular ischemia and leukomalacia, in comparison with 
normal neural development in an infant born through clear amniotic fluid without 
meconium aspiration syndrome. 
4. Further neurological abnormalities in children born through MSAF 
The vast majority of infants born through MSAF, even after successful management of MAS, 
do not present symptomatology suggestive of severe neurological disorder due to ante- or 
intrapartum fetal brain injury. An abnormal fetal heart rate tracing, a low Apgar score in the 
first and fifth minute after delivery or the presence of recurrent neonatal seizures and 
symptoms such as hypotonia or lethargy could predict possible CP in future. Nevertheless, 
even in the absence of these factors during the early postpartum period, an adverse 
neurodevelopmental outcome, as a result of fetal expose to MSAF, may appear during 
childhood.  
Children born through MSAF present a significantly increased risk for neurologic 
abnormalities in the 7th year of life, including quadriplegic CP, chronic seizures, 
hyperactivity, moderate or severe motor disability and severe mental retardation (MR) 
[Naeye RL., 1992]. 
Additionally, research studies support the existence of a positive correlation between fetal 
exposure to MSAF and future development of autistic disorder or difficulty with school 
learning procedures because of concentration deficit. 
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In conclusion, it is evident that major neurological disorders may arise from fetal or neonate 
brain injury. It must be the goal of obstetricians to minimize or even eliminate these 
complications, so catastrophic for the neurological and mental health of children, and to 
strive for the best perinatal management and thus outcome for both the mother and the 
neonate. 
5. Conclusions 
It is true that most infants born through MSAF will be neurologically healthy. Nonetheless, 
there is substantial documentation of the existence of a close relationship between 
MSAF/MAS and development of future neurological abnormalities, as well ample evidence 
that meconium passage may be the main etiological factor in the pathogenesis of 
neurological disorders in a significant percentage of children without other obstetrical 
complications.   
The intrauterine environment and the causes giving rise to intraamniotic meconium passage 
(i.e. hypoxia-anoxia status, intrauterine infection) are also involved in the pathogenesis of 
fetal brain injury due to MSAF, this possibly being activated via two as yet hypothesized 
pathways that may act in an either independent or synergic way. The direct vasoconstrictive 
and/or deleterious long-term in utero effect of meconium results in severe fetal brain injury 
due to the reduced venous return of oxygenated blood from the placenta to the fetus and/or 
the environment produced by proinflammatory fetal cytokines, oxidants and eicosanoids 
which is highly toxic for the fetal neural tissue. 
In the vast majority of cases, severe neurologic handicaps do not appear during the early 
postpartum period. However, the possibly remains that an adverse neurodevelopmental 
outcome combined with fetal exposure to MSAF could be diagnosed during childhood, or 
even in the first years of school, translated as pronounced learning difficulties. Cerebral 
palsy and severe mental retardation are major neurological disorders which are diagnosed 
more frequently in cases of children born through MSAF in comparison with those born 
through clear amniotic fluid. Their pathogenetic pathway is likely to have the same 
origination, which is severe fetal and neonatal brain injury. Needless to say, perinatal care 
has progressed vastly in the present day and the rate of these complications as well the 
mortality and morbidity rate after MSAF or MAS are correspondingly much decreased. 
However, bearing in mind the potential for these adverse outcomes, catastrophic for the 
neurological and mental future of the child, an uneventful late pregnancy and labor 
culminating in the optimal perinatal result for both the mother and the neonate must be the 
goal of every physician.    
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